Scinai Immunotherapeutics Ltd. Overview
Pro stress-test →Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bio-services business unit. With over 20 years of experience in recombinant protein process development and cGMP manufacturing, Scinai is on a mission to elevate drug development.
Strategic Profile
Pro stress-test →The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The dual-business-unit model leverages a mature CDMO operation to fund immunology research focused on NanoAbs (VHH antibody fragments). Scinai Immunotherapeutics announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN.
Competitive Landscape
Pro stress-test →Scinai competes in the crowded I&I biologics space against larger, better-capitalized biotech companies (Amgen, Regeneron, Incyte), while its CDMO business faces competition from established CRO/CDMOs like Lonza, Rentschler, and Ology Bioservices. The company's niche focus on boutique CDMO services and novel NanoAbs from Max Planck collaborations provides differentiation, but early-stage pipeline and capital constraints limit competitive reach.
Industry Context
Scinai Immunotherapeutics Ltd. operates in Inflammation and immunology (I&I) biologics development.
Key facts
Founded: N/A · Headquarters: Jerusalem, Israel · Employees: N/A · Revenue: $1.05M (9M 2025) · Market cap: N/A